Read Gene

Read Gene Inventory

The Inventory of Read Gene (RDG.WA) as of Nov 3, 2026 is 77,023.29 PLN. In the previous year, Inventory was 117,963.39 PLN — a change of -34.71% (lower).

Inventory

77,023.29PLN

YoY

-34.71%

Last updated:

Inventory of Read Gene is 2025 77,023.29 PLN. Inventory of Read Gene was 2024 117,963.39 PLN. It decreases by -34.71% lower compared to the previous year.

The Read Gene Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
20,350.00 PLN
Jan 1, 2019
29,300.00 PLN
Jan 1, 2020
3,550.00 PLN
Jan 1, 2021
26,640.89 PLN
Jan 1, 2022
30,148.25 PLN
Jan 1, 2023
129,176.45 PLN
Jan 1, 2024
117,963.39 PLN
Jan 1, 2025
77,023.29 PLN
The Read Gene Inventory history
YEARInventoryYoY
77,023.29PLN-34.71%
117,963.39PLN-8.68%
129,176.45PLN+328.47%
30,148.25PLN+13.17%
26,640.89PLN+650.45%
3,550.00PLN-87.88%
29,300.00PLN+43.98%
20,350.00PLN-12.36%
23,220.00PLN+10,454.55%
220.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Inventory of Read Gene is 77,023.29 PLN in 2025.

Inventory of Read Gene changed from 117,963.39 PLN to 77,023.29 PLN, representing a -34.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Read Gene since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Read Gene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Read Gene